Article Contents ::
- 1 The Brand Name MAGNOVA Has Generic Salt :: Cefepime
- 2 MAGNOVA Is From Company LUPIN Priced :: Rs. 118.32
- 3 MAGNOVA have Cefepime is comes under Sub class Cephalosporins of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Cephalosporins
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name MAGNOVA Has Generic Salt :: Cefepime
MAGNOVA Is From Company LUPIN Priced :: Rs. 118.32
MAGNOVA have Cefepime is comes under Sub class Cephalosporins of Main Class Anti Infectives
Main Medicine Class:: Anti Infectives Sub Medicine Class :: Cephalosporins
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Cefepime | INJ | Rs. 118.32 | VIAL |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / VIAL |
| MAGNOVA | LUPIN | 500MG | VIAL | Rs. 118.32 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From LUPIN :: MAGNOVA | Cefepime | Anti Infectives | Cephalosporins |
Indications for Drugs ::
Skin and skin structure infections, Urinary tract infection, Nosocomial pneumonia, Multiple drug resistant pneumonia, Neutropenia
Drug Dose ::
Adult: IV UTI 0.5-1 g 12 hrly for 7-10 days. Empirical therapy for febrile neutropenia 2 g 8 hrly for 7 days or until resolution of neutropenia. Moderate to severe pneumonia 1-2 g 12 hrly for 10 days. Complicated intra-abdominal infections 2 g 12 hrly for 7-10 days. Uncomplicated skin and skin structure infections 2 g 12 hrly for 10 days. Child: 2 mth – 16 yr: ?40 kg: 50 mg/kg every 12 hr for 7-10 days for Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis), Uncomplicated Skin and Skin Structure Infections and Pneumonia.. May be given via direct inj over 5 minutes or infuse over 30 minutes. For empiric therapy for febrile neutropenic patients 2 mth – 16 yr: <40 kg: 50 mg/kg every 8 hr for 7 days or until neutropenia resolves. Renal impairment: Haemodialysis: 1 g on the 1st day of treatment, followed by 0.5 g 24 hrly; dose should be given after haemodialysis on dialysis days and preferably at the same time each day. CAPD: Adult dose 48 hrly. CrCl (ml/min) <10 0.25-0.5 g 24 hrly. 11-29 0.5-1 g 24 hrly. 30-60 0.5-2 g 24 hrly. Contraindication ::
Hypersensitivity to cefepime or other cephalosporins.
Drug Precautions ::
Renal impairment; history of penicillin or cephalosporin allergy; lactation, pregnancy. Caution when used in patients with history of GI diseases, especially colitis. May decrease prothrombin activity; monitor prothrombin time in patients with poor nutritional state, renal or hepatic impairment and those on prolonged treatment. Prolonged treatment may result in overgrowth of nonsusceptible organisms, resulting in superinfection. Consider the possibility of Clostridium difficile associated diarrhoea in patients who present with diarrhoea after treatment. Caution when used in patients with a history of seizures.
Drug Side Effects ::
Positive Coombs’ test without haemolysis; rash, pruritus; diarrhoea, nausea, vomiting; fever, headache; pain and erythema at inj site; agranulocytosis; anaphylactic shock; leucopenia; neutropenia; thrombocytopenia.
Pregnancy category ::
2
Drug Mode of Action ::
Cefepime is a 4th generation cephalosporin which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs).
Drug Interactions ::
Increased potential for nephrotoxicity and ototoxicity of aminoglycosides. Increased risk of nephrotoxicity w/ potent diuretics (e.g. furosemide).
